[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100559978":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":23,"centralContacts":27,"locations":33,"responsibleParty":56,"collaborators":23,"id":58,"slug":23,"hasResults":59,"nctId":60,"briefTitle":61,"officialTitle":62,"acronym":63,"eligibilityCriteria":64,"healthyVolunteers":59,"sex":65,"minAge":66,"maxAge":23,"enrollmentInfo":67,"targetDuration":23,"studyType":70,"phases":71,"briefSummary":73,"conditions":74,"keywords":23,"overallStatus":36,"whyStopped":23,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":84,"locationsCount":85},{"fullName":5,"class":6},"Intermountain Health Care, Inc.","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Usual Care","ACTIVE_COMPARATOR","Patients will receive usual care for their LDL-C management.",[13],"Other: Usual Care",{"label":15,"type":16,"description":17,"interventionNames":18},"Clinical Pharmacy Team","EXPERIMENTAL","Patients will receive targeted care of their LDL-C through a pharmacist-driven management program.",[19],"Other: Clinical Pharmacy Team",[21,24],{"type":6,"name":15,"description":17,"armGroupLabels":22,"otherNames":23},[15],null,{"type":6,"name":9,"description":25,"armGroupLabels":26,"otherNames":23},"Patient will receive usual care for their LDL-C management.",[9],[28],{"name":29,"role":30,"phone":31,"phoneExt":23,"email":32},"Kirk U Knowlton, MD","CONTACT","801-507-4757","kirk.knowlton@imail.org",[34],{"facility":35,"status":36,"city":37,"state":38,"zip":39,"country":40,"cosmosGeoPoint":41,"geoPoint":46,"contacts":47},"Intermountain Healthcare Hospitals and Clinics","RECRUITING","Salt Lake City","Utah","84107","United States",{"type":42,"coordinates":43},"Point",[44,45],-111.89105,40.76078,{"lat":45,"lon":44},[48,50,54],{"name":29,"role":30,"phone":49,"phoneExt":23,"email":32},"801.507.4701",{"name":51,"role":30,"phone":52,"phoneExt":23,"email":53},"Heidi T May, PhD, MSPH","801-507-4700","heidi.may@imail.org",{"name":29,"role":55,"phone":23,"phoneExt":23,"email":23},"PRINCIPAL_INVESTIGATOR",{"type":57,"investigatorFullName":23,"investigatorTitle":23,"investigatorAffiliation":23,"oldNameTitle":23,"oldOrganization":23},"SPONSOR","100559978",false,"NCT06571162","A Pragmatic INitiative for LDL-C Management by a CLinical Pharmacist-Led Team Among Atherosclerotic CardiovascUlar DisEase Patients","A Pragmatic INitiative for LDL-C Management by a CLinical Pharmacist-Led Team Among Atherosclerotic CardiovascUlar DisEase Patients (The INCLUDE Trial)","INCLUDE","Inclusion Criteria:\n\n1. Male or female \\>18 years of age\n2. Receive follow-up care with Intermountain Health\n3. Value-based patient (as defined in the EDW)\n4. Documentation of an ASCVD diagnosis, by 1 of the following:\n\n   * Coronary artery disease (Primary inpatient CAD diagnosis during index encounter; Primary inpatient MI diagnosis during index encounter; PCI during index encounter; or CABG during index encounter\n   * Cerebrovascular accident (Primary inpatient ischemic stroke diagnosis during index encounter; Carotid endarterectomy during index encounter; or Carotid stent during index encounter)\n   * Peripheral arterial disease (Bypass or percutaneous intervention during index encounter)\n\nExclusion Criteria:\n\n1. Patient age \\\u003C18 years.\n2. Receipt of or expected receipt of palliative care, expected discharge to hospice, or long-term care facility (i.e., skilled nursing facility).\n3. Pregnant or lactating women","ALL","18 Years",{"count":68,"type":69},400,"ESTIMATED","INTERVENTIONAL",[72],"NA","Patients who had an ASCVD event at an Intermountain hospital will be screened for eligibility to be randomized. Subjects who meet eligibility criteria will be randomized 1:1 to receive targeted care of their LDL-C through a pharmacist-driven management program or not. Patients may opt-out of receiving LDL-C management by the pharmacy team at any time. The purpose of this program is to increase the proportion of patients who achieve guideline-based recommendations of LDL-C levels of \\\u003C70 mg\u002FdL by increasing statin and\u002For LLT adherence and LDL-C testing. Data collection as part of the study will continue until the last person randomized has had 1-year of follow-up.",[75],"Atherosclerotic Cardiovascular Disease","2025-05-01",{"date":78,"type":79},"2025-05-06","ACTUAL",{"date":81,"type":79},"2025-01-30",{"date":83,"type":69},"2028-09",{"name":5,"class":6},1]